June 1st 2020 TAGCyx established an Audit & Supervisory Board

TAGCyx Biotechnologies, Inc. (Tokyo, Japan) established an Audit & Supervisory Board. By establishing an Audit & Supervisory Board, we strengthen corporate governance and strive to promote business in a more sound manner.

Audit & Supervisory Board Member

Standing Statutory Auditor(External) Katsunori Suzuki
Auditor(External) Takahiro Kono
Auditor Yoshiyuki Yamakawa

Biography of Audit & Supervisory Board Member

■Katsunori Suzuki, Standing Statutory Auditor(External)

Graduated from Waseda University, Faculty of Science and Engineering, completed Waseda Business School. After working for IBM Japan, Sony, SoftBank, etc., he served as the director of the internal audit department at SKY Perfect JSAT, and also served as a corporate auditor of a group company. In 2020, he became a corporate auditor of Tagcyx.

■Takahiro Kono, Auditor(External)

After graduating from Meiji University, acquired a certified public accountant qualification. After engaging in audit work at Chuo Aoyama Audit Firm(PWC group), established Kono Tax and Accounting Office. Previously served as a lecturer at the Institute of Special Accounting, Meiji University. He has been a Corporate Auditor of Tagcyx since 2008.

■Yoshiyuki Yamakawa(External)

After graduating from Waseda University’s School of Political Science and Economics, worked for Nippon Life Insurance Company, then became Vice President of Sosei, and later established Hibiki Partners to provide IPO support. In addition, he has served as a number of outside directors including those related to pharmaceuticals. Appointed External Director of Tagcyx in 2016, a Corporate Auditor in 2020.



May 28th 2020 Notice of New management team

TAGCyx Biotechnologies, Inc. (Tokyo, Japan) are pleased to inform you that our new management team is as follows. Through the new management team, we will strengthen the drug discovery research and development capabilities and corporate governance, and strive for further progress in our business. We will continue to make every effort to meet everyone’s expectations, and we sincerely ask for your continued support.

Representative Director CEO Chizuko Koseki
Director CSO Susumu Muto
Director CFO Akiyoshi Kudose
Non-executive director Junya Yamazaki
Non-executive director Mikio Kawahara
Non-executive director Takayuki Okabuchi

Biography of management

■Chizuko Koseki, Representative Director CEO

After having a Ph.D. in Pharmacology from the University of Tokyo, a head of laboratory at the National Cardiovascular Center, a researcher at overseas universities, a director of drug discovery ventures, and as a VP of the Sosei Group achieved IPO. Joined Tagcyx in 2015 and has been in her current role since 2017.


■Susumu Muto, Director, CSO

After graduating from the Graduate School of Science of Shizuoka University, worked as a researcher at the Central Research Institute of Mochida Pharmaceutical and has a large number of drug discovery results. After that, he promoted research and development activities as a director in charge of drug discovery research and development at multiple drug discovery ventures. Joined Tagcyx in 2019 and has been in his current role since 2020.


■Akiyoshi Kudose, Director, CFO

After graduating from the Graduate School of Science and Engineering of Waseda University, worked for Panasonic and acquired a certified public accountant qualification. After engaging in audit work at EY ShinNihon LLC, served as responsible person of finance and accounting division at CRO and IT company contributed to overseas expansion, fund raising, M&A, IPO. Joined Tagcyx in 2020 in his current role.


■Junya Yamazaki, Non-executive director

After completing the doctoral course at the Graduate School of Life Sciences, Kyoto University, engaged in pharmaceutical-related investment research at Goldman Sachs Securities, Takeda Pharmaceutical, etc., joined in UTEC in 2019, and became a non-executive director of Tagcyx.


■Mikio Kawahara, Non-executive director

After graduating from the Graduate School of Engineering, the University of Tokyo, worked in Toppan Printing and worked as a representative director at pharmaceutical venture company. etc., joined in UTokyo IPC in 2016, in charge of investment and business development. In 2020, he became a non-executive director of Tagcyx.


■Takayuki Okabuchi, Non-executive director

Registered as a lawyer after graduating from the Faculty of Law, Keio University. After working for a law firm, opened Tsukishima Kachidoki Law Office. Served as an external officer for drug discovery ventures. Appointed as a non-executive director of Tagcyx in 2020 (commencement on June 1st 2020).



May 5th 2020 TAGCyx raises approximately 200 million JPY

TAGCyx Biotechnologies, Inc. (Tokyo, Japan) has raised approximately 200 million JPY from UTokyo Innovation Platform Co., Ltd. (Tokyo)

TAGCyx is developing unique DNA aptamer called “Xenoligo” in healthcare field, using proprietary artificial nucleic acid base pair technology. Aptamers, also known as “chemically synthesizable antibodies,” are oligo nucleic acids (DNA or RNA) and peptides that bind to specific molecules, and act like antibody antigen interaction. Xenoligo has following features. ① high binding affinity to proteins by particular hydrophobic interaction of artificial bases (you can select a high binding candidate molecule from a huge DNA library of 1014 or more that can be randomly generated), ② stabilization by proprietary Mini-hair pin technology (realization of sufficient stability as a drug), ③ low manufacturing cost (it can be manufactured by chemical synthesis unlike antibody drugs), and ④ high versatility (applicable to targets that antibody drugs are difficult to target).

Based on the platform technology of Xenoligo, TAGCyx has concentrated management resources in the drug discovery business since 2016, and through multiple steps of financing, has entered into several collaboration agreements with pharmaceutical and healthcare companies. Achieving this funding, TAGCyx will accelerate R&D for changing paradigm to human healthcare.

Feb 19th 2020 TAGCyx and GC Pharma has entered into collaborative research and development for conducting various pre-clinical studies of TAGX-0004

February 19 2020: TAGCyx and GC Pharma (formerly known as Green Cross Corporation) has entered into collaborative research and development for conducting various pre-clinical studies of TAGX-0004.

TAGCyx has signed Joint Research and Development Agreement with GC Pharma (KRX: 006280) in relation to pursuing various pre-clinical studies of TAGX-0004, an anti-human vWF DNA aptamer containing proprietary artificial nucleotide.

TAGCyx has invented artificial nucleic acid base pair technology that enables to produce high affinity and selective DNA aptamers “Xenoligo®”, that is regarded to be an alternative to antibody therapeutics.


GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century.


TAGX-0004 is an innovative DNA aptamer therapeutics developed by TAGCyx aiming to treat thrombotic disorders such as brain and cardiac infarction, and currently under development for rare disease called acquired thrombotic thrombocytopenic purpura (aTTP).  TAGCyx has accumulated many pharmacological data to date in collaboration with a Japanese leading scientist in the field, Professor Masanori Matsumoto, Nara Medical University.


Dr. Chizuko Koseki, Chief Executive Officer of TAGCyx added “Together with GC Pharma, we believe our aptamer will be a key therapeutic option for the patient of aTTP, and eventually for other thrombotic diseases. GC Pharma’s deep insight will realize TAGCyx’ mission to provide an effective treatment to various challenging diseases”.


Under the agreement, GC Pharma will fund the development cost for pre-agreed pre-clinical studies, and TAGCyx will conduct the studies with CROs. Under the confidentiality of the agreement, further detail of the research is not disclosed.